Patents by Inventor Xinling Yang

Xinling Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified hemofiltration method for clearing peripheral ?-synuclein aggregates in patient with neurodegenerative disease
    Patent number: 12555686
    Abstract: A modified hemofiltration method for clearing peripheral ?-synuclein aggregates in patients with neurodegenerative diseases is provided, which falls into the field of medicine. Specifically, a ratio S of synuclein dimers in blood is obtained; a blood flow velocity and an exchange membrane area for hemofiltration are determined through clinical trial data or historical literature data; hemofiltration is performed by the determined blood flow velocity and exchange membrane area, a calculation model of the ratio S of different synuclein dimers and an exchange membrane aperture D required for hemofiltration is constructed by linear regression; a clearance rate of synuclein dimers can be estimated by setting hemofiltration parameters with the calculation model. It is found that hemofiltration is beneficial to reducing the level of peripheral ?-synuclein aggregates in patients with neurodegenerative diseases.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: February 17, 2026
    Assignees: The First Affiliated Hospital of Guangzhou Medical University, Jiangxi Leyun Health Technology Co., Ltd
    Inventors: Mingshu Mo, Wenyuan Guo, Guoyun Chen, Xiang Chen, Lin Lu, Hangxu Mao, Yangfu Luo, Lianqun Wang, Xinling Yang, Xiaokang Zhang, Pingyi Xu
  • Modified Hemofiltration Method for Clearing Peripheral ?-synuclein Aggregates in Patient with Neurodegenerative Disease
    Publication number: 20220415517
    Abstract: A modified hemofiltration method for clearing peripheral ?-synuclein aggregates in patients with neurodegenerative diseases is provided, which falls into the field of medicine. Specifically, a ratio S of synuclein dimers in blood is obtained; a blood flow velocity and an exchange membrane area for hemofiltration are determined through clinical trial data or historical literature data; hemofiltration is performed by the determined blood flow velocity and exchange membrane area, a calculation model of the ratio S of different synuclein dimers and an exchange membrane aperture D required for hemofiltration is constructed by linear regression; a clearance rate of synuclein dimers can be estimated by setting hemofiltration parameters with the calculation model. It is found that hemofiltration is beneficial to reducing the level of peripheral ?-synuclein aggregates in patients with neurodegenerative diseases.
    Type: Application
    Filed: October 19, 2021
    Publication date: December 29, 2022
    Inventors: Mingshu Mo, Wenyuan Guo, Guoyun Chen, Xiang Chen, Lin Lu, Hangxu Mao, Yangfu Luo, Lianqun Wang, Xinling Yang, Xiaokang Zhang, Pingyi Xu